Robert A. Uger
Mississauga, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.
Journal: Frontiers in immunology
Published: October 28, 2024
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.
Journal: NPJ precision oncology
Published: November 22, 2022
Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides.
Journal: Cancers
Published: October 30, 2021
The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.
Journal: Cancer immunology, immunotherapy : CII
Published: May 11, 2021
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Journal: The Lancet. Haematology
Published: April 12, 2021
Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.
Journal: Blood advances
Published: October 05, 2020
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2020
Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Journal: British journal of haematology
Published: August 02, 2020
SIRPαFc treatment targets human acute myeloid leukemia stem cells.
Journal: Haematologica
Published: February 13, 2020
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma.
Journal: Nature medicine
Published: November 21, 2019
Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy.
Journal: Expert opinion on biological therapy
Published: October 31, 2019
Last Updated: 09/26/2026